BHCM
ZNTL icon

Brevan Howard Capital Management’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Brevan Howard Capital Management’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,063
Closed -$110K – 2644
2026
Q1 		$110K Buy
+47,063
New +$122K ﹤0.01% 2002
2025
Q1 		– Sell
-26,351
Closed -$79.8K – 1525
2024
Q4 		$79.8K Buy
26,351
+10,903
+71% +$35.7K ﹤0.01% 978
2024
Q3 		$56.8K Sell
15,448
-5,791
-27% -$21K ﹤0.01% 1091
2024
Q2 		$86.9K Buy
21,239
+7,635
+56% +$85.3K ﹤0.01% 978
2024
Q1 		$214K Buy
+13,604
New +$187K ﹤0.01% 776

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Brevan Howard Capital Management's ZNTL Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Zentalis Pharmaceuticals (ZNTL) in Q2 2026, closing a stake of 47,063 shares — an estimated $110K sold.

Brevan Howard Capital Management first reported a position in ZNTL in Q1 2024 and held it in 5 quarters. The position peaked at $214K in Q1 2024. 114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Zentalis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 47,063 Zentalis Pharmaceuticals shares in Q2 2026, an estimated $110K.
  • Brevan Howard Capital Management first reported a position in Zentalis Pharmaceuticals in Q1 2024 and held it in 5 quarters.
  • Brevan Howard Capital Management's Zentalis Pharmaceuticals position peaked at $214K in Q1 2024.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.